Press Releases on November 14, 2024 - EIN Presswire - Press Release Distribution Service

Published on November 14, 2024 - 21:05 GMT

Aqua Metals Announces Progress on Operational Achievements and Ongoing Commercial Development, Reports Third Quarter 2024 Results

RENO, Nev., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today reported financial results for the third quarter ended September 30, 2024 and provided an update on its operations, …

Distribution channels: Business & Economy, Electronics Industry ...

Published on November 14, 2024 - 21:05 GMT

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi ...

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:05 GMT

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American ...

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:05 GMT

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, …

Distribution channels: Business & Economy, Technology ...

Published on November 14, 2024 - 21:05 GMT

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of Nitric Oxide (NO) to improve the lives …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

iPower Reports Fiscal First Quarter 2025 Results

RANCHO CUCAMONGA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and data-driven ecommerce services provider and online retailer, today announced its financial results for the fiscal first quarter …

Distribution channels: Business & Economy, IT Industry ...

Published on November 14, 2024 - 21:05 GMT

180 Degree Capital Corp. Reports Net Asset Value Per Share (“NAV”) of $4.40 as of September 30, 2024, and Will Host Conference ...

MONTCLAIR, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180 Degree Capital” and the “Company”), today reported its financial results as of September 30, 2024, and noted additional developments from the fourth quarter of …

Distribution channels: Business & Economy, Culture, Society & Lifestyle ...

Published on November 14, 2024 - 21:05 GMT

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

Revenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential Quarter of Growth, and 6.4% Compared to the Same Period in 2023 Significant Reduction in Overall Operating Expenses of 40.6% in the First Nine …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, ...

Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO™ I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:05 GMT

Polar Power Reports Third Quarter 2024 Financial Results

GARDENA, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the third quarter of 2024. Q3 2024 …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:05 GMT

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 14, 2024 - 21:05 GMT

Rekor Systems Reports Third Quarter 2024 Financial Results

Highlights Q3 2024 gross revenue increased 16% to $10.5 million compared to $9.1 million in Q3 2023 Q3 recurring revenue increased 14% to $5.5 million compared to $4.8 million Rekor Discover™ now on the Florida DOT Approved Product List, and deployments …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Li Bang International Corporation Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option

Jiangyin, China, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Li Bang International Corporation Inc. (Nasdaq: LBGJ) (the “Company” or “Li Bang”), a company engaged in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China, …

Distribution channels: Banking, Finance & Investment Industry ...

Published on November 14, 2024 - 21:05 GMT

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Airship AI Reports Third Quarter 2024 Financial Results

Third Quarter 2024 Net Revenues of $2.9 Million, Gross Profit of $2.2 Million and Gross Margin of 75% 2024 Net Revenue of $19.9 Million Through the 9 Months ended September 30, 2024 Represents a 61% Increase over FY 2023 Net Revenue of $12.3 Million New …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

T2 Biosystems Announces Third Quarter 2024 Financial Results

LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the …

Distribution channels:

Published on November 14, 2024 - 21:05 GMT

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and …

Distribution channels: